Mercer Group licences technology to US firm

Last updated 12:42 09/12/2013
MGL 0.020 0.00 0.00%

Click for a detailed chart

Relevant offers


Milk powder scam raises questions about Fonterra, expert says Bitter lesson for investors as Wynyard calls in administrators AJ Hackett to open new "world's highest bungy" - in China New York enacts restrictions on Airbnb, with fines of up to $10,000 Court action on 'shonky' steel mesh creates pressure for government inquiry Female lawyers charge-out rates lag behind their male colleagues Weight Watchers campaign joins list of PR blunders Opportunist builders, dodgy steel and shonky standards create new building crisis 'worse than leaky homes' Troubled property developer Augustine Lau taken to court for toilets emptying into stream Skills shortage results in firms looking internally to fill roles, recruitment firm says

The stainless steel manufacturer, Mercer Group, has licensed its "breakthrough sterilisation" technology to a large American corporation in the medical sector, which it is not naming.

Mercer, headquartered in Christchurch and controlled by businessman Humphy Rolelston, said given the size of the United States market and the partner Mercer has signed with, "the transaction is likely to be material to the value of the company".

The shares rose 2 cents to 21c in early trading today.

"The S-Clave technology is a breakthrough sterilisation process that allows items to be sterilised inside a non-porous bag and then sealed so that the items can be stored safely without contamination," the company said.

The deal should result in Mercer receiving an average royalty of at least 5 per cent from the S-Clave equipment and the bag sales in North America.

However, sales are three to four years away and dependent on regulatory approvals in the US, the company said.

Mercer will receive an upfront payment of $800,000 net, plus further payments of up to at least US$1 million (NZ$1.2m) after three years. Milestones were in place for the agreement to remain exclusive.

Mercer said the licence agreement, exclusive for the North American market in the medical and laboratory fields, provided exclusive use of the technology in North America and that could include manufacturing of it.

Ad Feedback

- Fairfax Media

Special offers

Featured Promotions

Sponsored Content